Across TCGA pan-cancer cohorts, IGLV4-69 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IGLV4-69 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IGLV4-69 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IGLV4-69 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and GBM are the cancer types where IGLV4-69 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	IV	0.836	0.491	.024	3	view →
LUAD	DFS	Median	III,IV	0.716	0.356	.020	2	view →
GBM	DFS	Median	All	0.422	0.214	.020	2	view →
LSCC	DFS	Median	All	0.919	0.615	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: IGLV4-69 tumor-vs-normal RNA expression · all IGLV4-69 data types